Singapore-based Napean Trading & Investment disclosed a new position in BillionToOne, acquiring 233,333 shares valued at $19,095,973. This new position accounts for 3.71% of the fund’s reportable U.S. equity assets under management. Top holdings include Robinhood and Navan.

BillionToOne shares were priced at $88.61 on February 13, 2026, up 48% from their November IPO price of $60. The company offers precision molecular diagnostics, generating revenue through advanced molecular testing services for healthcare providers and laboratories, focusing on prenatal care and oncology diagnostics.

This significant $19.1 million position in BillionToOne represents a meaningful allocation at 3.71% of assets, alongside larger tech bets. The company reiterated 2025 revenue guidance of $293 million to $299 million and expects $415 million to $430 million in 2026 revenue. Management anticipates positive GAAP operating income for both years.

Consideration for investing in BillionToOne: The Motley Fool Stock Advisor team did not include it in their 10 best stocks to buy now. However, Stock Advisor boasts a total average return of 884%, outperforming the S&P 500. Don’t miss out on the latest top 10 list and join an investing community focused on individual investors.

Read more at Yahoo Finance: Why a New $19.1 Million Position Could Matter Now